AE 37

Drug Profile

AE 37

Alternative Names: AE37; AE37 peptide/GM-CSF HER2 peptide vaccine; AE37 vaccine; Cancer vaccine AE37 - Antigen Express; Cancer vaccine AE37 - Generex-Biotechnology; Cancer vaccine HER2/neu Antigen Express AE37; Cancer vaccine HER2/neu Generex Biotechnology AE37; Her-2/neu Breast cancer; Her-2/neu Prostate cancer; Ii-key hybrid cancer vaccine AE37; Ii-key hybrid HER2/neu vaccine Antigen Express AE37; Ii-key hybrid HER2/neu vaccine Generex Biotechnology AE37; Ii-Key/Her-2/neu(776-790) vaccine; Modified HER2/neu peptide AE37 vaccine

Latest Information Update: 09 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antigen Express
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants; Regulatory T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Prostate cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 07 Dec 2017 Generex and Shenzhen BioScien Pharmaceuticals agree to co-promote and co-develop AE 37 in China (including Taiwan, Hong Kong, and Macau) for Prostate cancer
  • 31 Jul 2017 Merck and Antigen Express enter into clinical trial collaboration agreement to develop AE 37 in combination with pembrolizumab for Breast cancer
  • 31 Jul 2017 Merck and Antigen Express plan a phase II trial of AE 37 in combination with pembrolizumab for triple-negative Breast cancer (Metastatic disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top